<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503059</url>
  </required_header>
  <id_info>
    <org_study_id>FPA-ETA-2014-01</org_study_id>
    <nct_id>NCT02503059</nct_id>
  </id_info>
  <brief_title>Etanercept Survival in Elderly Population</brief_title>
  <official_title>Etanercept Survival in Elderly Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the 3-year survival of etanercept in patients over 60 years with psoriasis in
      moderate / severe plaque and the reasons that led to the abandonment. Besides factors that
      might have had a positive or negative influence on adherence to treatment and analysis of
      efficacy (PASI 75) and safety will be identified.

      All variables were collected through retrospective review of medical records of patients
      dermatology unit are made.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>primary ineffectiveness in patients with etanercept treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants not achieve PASI 50 response at 12 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary ineffectiveness in patients with etanercept treatment</measure>
    <time_frame>24 weeks (duration of treatment with etanercept)</time_frame>
    <description>Number of participants with Poor adherence to treatment with etanercept&quot;,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ineffectiveness of treatment in localized lesions in patients with etanercept treatment</measure>
    <time_frame>24 weeks(duration of treatment with etanercept)</time_frame>
    <description>Despite having achieved a good response PASI no improvement in critical injuries</description>
  </primary_outcome>
  <primary_outcome>
    <measure>primary ineffectiveness in patients with etanercept treatment</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants not achieve PASI 75 response at 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events during treatment with etanercept</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with disease remission</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with Poor adherence to treatment with etanercept</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with Conditions requiring hospitalization and / or surgery</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Psoriasis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients over 60 who received etanercept for the treatment of moderate / severe
        psoriasis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with moderate / severe psoriasis (with / without psoriatic arthritis,PAs)
             defined by: PASI(Psoriasis Area and Severity Index)&gt; 10 and / or BSA(Body Surface
             Area)&gt; 10% and / or DLQI(Dermatology Life Quality Index)&gt; 10

          -  PASI&gt; 10 and / or BSA(Body Surface Area)&gt; 10% and / or DLQI(Dermatology Life Quality
             Index)&gt; 10

          -  Over 60 years of age at the start of treatment

          -  Receiving etanercept at any time

          -  Available history in the Dermatology

        Exclusion Criteria:

          -  Patients with insufficient clinical data in the medical record
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Herrera Ceballos, MD</last_name>
    <role>Study Director</role>
    <affiliation>H.U. Virgen de la Victoria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Andújar</name>
      <address>
        <city>Jaén</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital la Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

